Ciracadian Ocular Perfusion and Ocular Blood Flow

This study is currently recruiting participants.

Verified January 2012 by Alcon Research

First Received on December 1, 2008. Last Updated on January 12, 2012 History of Changes

Sponsor:	Alcon Research
Information provided by (Responsible Party):	Alcon Research
ClinicalTrials.gov Identifier:	NCT00800540

Purpose

Compare the short term effects of two IOP-lowering medications on ocular perfusion pressure, ocular blood flow, circadian IOP and blood pressure in patients with glaucoma.

Condition	Intervention	Phase
Glaucoma	Drug: AZARGA Drug: COMBIGAN	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma

U.S. FDA Resources

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Diastolic ocular perfusion pressure [ Time Frame: after 6 weeks of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Circadian ocular perfusion pressure [ Time Frame: after 6 weeks of treatment ] [ Designated as safety issue: No ]

Estimated Enrollment:	36
Study Start Date:	February 2009
Estimated Study Completion Date:	July 2012
Estimated Primary Completion Date:	July 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 AZARGA	Drug: AZARGA Brinzolamide 10 mg/ml / Timolol 5 mg/ml, Eye drops, suspension
Active Comparator: 2 COMBIGAN	Drug: COMBIGAN Brimonidine 2 mg/ml / Timolol 5 mg/ml, Eye drops, solution

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18 years of age or older
Either sex
Open-Angle Glaucoma in at least one eye
Requiring more than one IOP lowering medication
Mean IOP ≥ 23 mmHg at one time point during Eligibility/Baseline Visit (7 IOP measurements) and ≤ 32 mmHg at all time points at screening, safety, eligibility/Period 1 Baseline Visits

Exclusion Criteria:

Severe central visual field loss in either eye
Shaffer angle grade < III
Cup/disc ratio > 0.8 in either eye
Previous glaucoma surgery
Intraocular surgery < 3 months
Best-corrected VA > 0,6 logMAR
Contact lens wear
Allergy/hypersensitivity to study medication
Glucocorticoid must be discontinued 4 weeks prior to the screening visit and not be used during the study
Cardiovascular disease or uncontrolled hepatic, renal diseases that would require use of medications that could affect IOP or blood pressure
Medication that could affect IOP or Blood Pressure
Recent use (< 4 weeks prior to the study) of aspirin (> 1 gram)
Bronchial asthma or severe chronic obstructive pulmonary disease
Diabetic retinopathy
Any abnormality preventing reliable tonometry

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00800540

Contacts

Contact: Alcon Call Center

1-888-451-3937

Locations

United States, Texas
Contact Alcon Call Center For Trial Locations	Recruiting
Fort Worth, Texas, United States, 76134
Contact: Alcon Call Center

Sponsors and Collaborators

Alcon Research

More Information

No publications provided

Responsible Party:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00800540 History of Changes
Other Study ID Numbers:	C-07-16, eudract Number 2007-005936-99
Study First Received:	December 1, 2008
Last Updated:	January 12, 2012
Health Authority:	United States: Institutional Review Board

Keywords provided by Alcon Research:

glaucoma
ocular perfusion pressure
ocular blood flow
open angle glaucoma requiring more than one IOP-lowering medication

Additional relevant MeSH terms:

Glaucoma
Ocular Hypertension
Eye Diseases

ClinicalTrials.gov processed this record on May 24, 2012